Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Cancer. 2017 Jun 22;123(19):3763–3771. doi: 10.1002/cncr.30818

Figure 1. Markov model of post-ASCT brentuximab vedotin consolidation versus active surveillance with use of brentuximab vedotin rescue at time of HL progression.

Figure 1

ASCT indicates autologous stem cell transplantation; BV, brentuximab vedotin.